Human Growth Hormone Market- Healthcare sector By Current Industry: Pfizer Inc., Genetech Inc., Merck & Co., Eli Lilly And Company, Novo Nordisk

Major driver for human growth hormone market is new mergers and acquisitions. For instance, in 2014, Pfizer Inc., a U.S.-based pharmaceutical company, merged with OPKO Health Inc., a U.S.-based company, to develop a long acting growth hormone (hGH-CTP) and to bring innovative treatments for growth hormone deficient patients. hGH-CTP is more convenient, as the patients need to take just one injection in a week rather than daily doses. hGH-CTP has an orphan drug designation in the U.S. and Europe for adults and children with growth hormone deficiency.

Request for a sample of this research report @ www.coherentmarketinsights.com/insight/request-sample/1859

Robust pipeline is also expected to support the growth in human growth hormone market size. For instance, Somapacitan sponsored by Novo Nordisk A/S, a Denmark-based company, completed phase 3 clinical trials in 2017. This drug is used for the treatment of growth hormone deficiency in adults. MOD-4023 sponsored by Opko Biologics, an Israel-based company, completed phase 2 clinical trials in 2015. High prevalence of growth hormone deficiency is another factor boosting growth of human growth hormone market. According to a survey conducted by the National Organization for Rare Diseases (NORA) in 2015, over 10,000 children and 50,000 adults have growth hormone deficiency in the U.S.

Europe human growth hormone market is expected to witness significant growth due to mergers and acquisitions. For instance, in 2017, Ferring Pharmaceuticals S.A., a pharmaceutical company, acquired a product i.e. Zoma Jet of Antares Pharma Inc, a pharmaceutical company. Zoma Jet is a needle free auto injectable device. Ferring Pharmaceuticals S.A acquired Zoma Jet in order to increase use of Zomacton (Injectable somatropin hGH). Zoma Jet is used to deliver Zomacton for the treatment of growth hormone deficiency in children and Turner’s syndrome in girls.

Request for Customization of Research Report @ https://www.coherentmarketinsights.com/insight/request-customization/1859

By acquiring the injectable device Zoma Jet, would eventually lead to increase in use of the drug, Zomacton, which will further encourage Ferring Pharmaceuticals to develop better treatment options for growth hormone deficiency, thereby resulting in growth of the human growth hormone market. Asia Pacific is expected to grow over the forecast period due to robust pipeline. For instance, Cinna Tropin sponsored by Cinnagen, an Iran-based company, completed phase 3 clinical trials in 2017. This drug is used to treat idiopathic short stature in children and adults.

North America is expected to hold dominant position in the global human growth hormone market due to new biosimilar approvals by Health Canada for biosimilar of human growth hormone drugs. For instance, in 2015, Health Canada approved the first generic biological called as PROmnitrope. PROmnitrope is a recombinant human growth hormone used to treat deficiency of growth hormone in adults as well as children. This can encourage new generic version of drugs, thereby fueling the human growth hormone market growth.

Make an inquiry for purchasing this report @ www.coherentmarketinsights.com/insight/buy-now/1859

However, strict rules and regulations for the use of human growth hormone by athletes and sports professionals is expected to restrain growth of human growth hormone market. The Food and Drug Administration (FDA) and the International Olympic Committee had banned the use of human growth hormone for sports professionals in 2006.

Key players operating in the global human growth hormone market include Pfizer Inc., Genetech Inc., Merck & Co., Eli Lilly And Company, Novo Nordisk, Sandoz International GmbH, Ferring Holding SA, and Ipsen.

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

This release was published on openPR.